Skip to main content
. 2020 Oct 1;26(3):e435–e444. doi: 10.1002/onco.13527

Figure 2.

Figure 2

Time to development of grade ≥2 fatigue. Cumulative incidence functions for time to development of grade ≥2 fatigue for (A) carboplatin plus paclitaxel and (B) paclitaxel alone according to age group and for (C) carboplatin plus paclitaxel and (D) paclitaxel alone according to performance status group.Abbreviations: AE, adverse event; PS, performance status.